Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Industry Won’t Grow If Pricing Premium Ended, Pharma Leaders Tell Govt
April 14, 2015
- JPA’s Abe Says Link between Pricing Premium and New Drug Development Blurry
April 13, 2015
- PAFSC’s Second Committee to Review PegIntron, Talion on April 24
April 13, 2015
- Consumer Affairs Agency Warns Public of Adverse Reaction Risks of OTC Drugs
April 10, 2015
- Set Ceiling for Health Coverage of OTC-Like Drugs: Govt Panel
April 9, 2015
- Chuikyo to Focus Sights on Unused Medication, Long-Term Prescriptions in Discussions
April 9, 2015
- Orphan Designation System Should Be Adjusted for Factors Including Company Scale: Report
April 8, 2015
- Most Cancer Drugs Would Cost Over 1 Million Yen a Month under Patient-Initiated Mixed Care: NCC
April 7, 2015
- MEXT Secures FY2015 Budgets for Generic Promotion Subsidy Project
April 7, 2015
- Overlapping of All-Case Surveys and EPPV Inefficient: Mr Uda of FPMAJ
April 7, 2015
- PMDA Reviewing Plavix for Risk of Acute Generalized Exanthematous Pustulosis
April 6, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 23 - April 5
April 6, 2015
- Govt, Pharma Leaders to Hold Policy Dialogue on April 13
April 6, 2015
- Abe Pins Hopes of Innovation on AMED
April 6, 2015
- MHLW to Accept Applications for “Sakigake” Designation from May 8
April 6, 2015
- MHLW Orders Revision of Package Inserts for Cetuximab, Panitumumab
April 3, 2015
- MHLW Requires Municipalities to Compile Generic Promotion Plans for Welfare Recipients
April 3, 2015
- AMED Inaugurated with Diverse Talents as Unit Heads
April 2, 2015
- MHLW Notifies of New Criteria for Orphan Drug Designation
April 2, 2015
- MHLW Notifications Prod Generic Use under High-Cost Healthcare Benefit System
April 2, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…